Gilead Acquires Tubulis for $3.15B Upfront, Bolstering Oncology Pipeline
GILD sits 26% above its 52-week low of $104.46.
Summary
Gilead Sciences acquired Tubulis for $3.15 billion upfront, with up to $1.85 billion in additional milestones, significantly expanding its oncology pipeline with new ADC platforms and clinical assets. This follows a series of large acquisitions, including the $7.1 billion Arcellx deal, and a recent $3 billion senior notes offering to fund these strategic moves. While bolstering a key growth area, this new acquisition adds to the substantial IPR&D charges that led Gilead to revise its full-year outlook to a net loss. Separately, lab tests indicate Gilead's remdesivir is active against Bundibugyo ebolavirus, potentially broadening its application.
At the time of this announcement, GILD was trading at $131.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.